The Global Lung Cancer Coalition (GLCC) announced today, at the 15th World Conference on Lung Cancer (WCLC) in Sydney, Australia, a campaign, supported by Boehringer Ingelheim (BI), to increase the knowledge and understanding of real world challenges facing individuals and families battling lung cancer. 'Lung Cancer: We're Listening' will gather much needed feedback from individuals touched by lung cancer - including patients, carers, family members, friends, healthcare professionals and work colleagues.

Amgen (NASDAQ:AMGN) has announced results for the third quarter of 2013. Total revenues increased 10 percent to $4,748 million, with 11 percent product sales growth driven by strong performance across the portfolio, particularly from Neulasta® (pegfilgrastim), Enbrel® (etanercept), Prolia® (denosumab) and XGEVA® (denosumab).

Bristol-Myers Squibb Company (NYSE:BMY) has reported results for the third quarter of 2013 highlighted by the strong performance of key marketed products such as Yervoy, Orencia and Sprycel, the presentation of important clinical data for its immuno-oncology pipeline, and the presentation of key cardiovascular outcomes data for Onglyza®.

Group net sales increased 4% (+6% cc) to USD 14.3 billion in the third quarter, with all divisions contributing to growth in constant currencies. Currency had a negative impact of 2 percentage points, mainly from the weakened yen and weakening emerging market currencies. Excluding the impact of patent expiries, underlying net sales grew 10% in constant currencies.

Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with F. Hoffmann-La Roche ("Roche") to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective Jan. 1, 2014. Roche has held the rights to filgrastim and pegfilgrastim under license from Kirin-Amgen, Inc. (a joint venture between Amgen and Kirin Holdings Co. Limited, of Japan) in Eastern Europe, Latin America, Asia, the Middle East and Africa since 1989.

GlaxoSmithKline plc (LSE/NYSE: GSK) and Genmab A/S (OMX: GEN) have announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for the use of Arzerra® (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy.

Group sales rose 6% to 34.9 billion Swiss francs in the first nine months of the year due to strong demand for Roche's HER2 breast-cancer treatments, as well as higher sales of Avastin and clinical laboratory products from the Diagnostics Division. For the fifth consecutive year Roche was ranked as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry in the Dow Jones Sustainability Index (DJSI), highlighting the Group's commitment to responsible business practices and the creation of long-term value.